Still No Death Blow for Insurers (AET, HUM, UNH)
The Obama speech to a joint session of Congress last night did not exactly deliver the death blow to health insurers. It also did not give the insurers the keys to the palace. Despite…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 340BioTech Hostile Takeover: Biogen Plays For Facet
Facet Biotech Corporation (FACT) confirms that it is in receipt of Biogen Idec Inc.’s (BIIB) letter dated September 4, 2009 offering $14.50 per share for all of the outstanding shares of Facet. Facet shares…
The Swine Flu Ferret Defense
There are dozens of biotech companies and several Big Pharma firms that hope to make money on swine flu treatments, mostly vaccines. They are driven by the WHO’s estimate that nearly a third of…
Brand Image: Did Mackey Really Hurt Whole Foods? (WFMI)
Whole Foods Market, Inc. (NASDAQ: WFMI) has been under fire of late from outside groups, although this time it is not over the founder’s secret web posting, not over a merger and antitrust issues,…
When Key Biotechs Have Low P/E’s & Value Screens (AMGN, BIIB, CEPH, CBST, GENZ, PDLI)
It usually takes an event or a series of events for biotech stocks to ever look cheap compared to the overall market or even to sub-sectors within health care. They generally trade at higher…
The Coming Swine Flu Recession
There was a lot of analysis that went on when the early cases of swine flu were reported from Mexico. The WHO began to talk about a pandemic which raised the specter of the…
Mylan’s (MYL) Deeply Flawed Legal And PR Move
Robert Coury, the CEO of Mylan (MYL), his general counsel, and public affairs staff don’t know how to quit when they are ahead. The company objected to a story in the Pittsburgh Post-Gazette that raised…
New Biotech Survey Says Sector Will Outperform
Biotechnology Industry Organization (BIO.org) has conducted a survey of 80 investors, analysts, and venture capital executives with Thomson Reuters to preview their opinions of the biotech sector and expectations for 2009. The study was…
Emdeon IPO: Healthcare Reform Beneficiary (EM)
Emdeon Inc. (NYSE: EM) is today’s ‘other’ initial public offering. The company priced 23,700,000 shares of its common stock at a price of $15.50 per share. Not all proceeds are going back into the…
Genzyme Taking Aim At Resolution (GENZ)
Genzyme Corp. (NASDAQ: GENZ) has taken steps to remedy its situation with the FDA and to remedy its image. Genzyme issued some new guidance with an investor update and said it would discard the…
Dendreon Gives Quarterly Report & Provenge Updates (DNDN)
Dendreon Corp. (NASDAQ: DNDN) has its quarterly results out, although it is via SEC Filing rather than via a press release. We had this on deck for a report this week and a conference…
The War On Diabetes Heats Up (NVO, AMLN, LLY, MNKD, PFE, VVUS, BMY, AZN, ARNA, GERN, STEM, OREX, GNBT, SPEX, ORMP, HDIX, PODD)
Diabetes is becoming an epidemic in the U.S. and the Western World. The ties to obesity are often direct, so the potential treatments are often directly tied as well. We did a recent dig…
Unemployment USA: Moving America To North Dakota
Millions of out of work Americans may wish that they lived in North Dakota, no matter how harsh the winters can be. The state had an unemployment rate of only 4.2% compared with the…
Long Line of Biotech Secondary Stock Offerings (MNKD, IDIX, ISPH, ARIA, ONTY, NBY, SOMX, ARNA, OXGN)
It seems that there is another endless line of biotech and emerging pharmaceutical companies which have raised cash or have filed to raise cash. MannKind Corporation (NASDAQ: MNKD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and…
MannKind Raises Over $50 Million (MNKD, PFE)
MannKind Corporation (NASDAQ: MNKD) is getting hit after the company announced that it priced a secondary offering of 7,400,000 shares of its common stock. While the press release does not say what price the…